Difference between revisions of "Tamibarotene (Amnoid)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=571791 NCI Drug Dictionary]: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium. |
| − | = | + | ==Diseases for which it is used== |
| + | *[[Acute promyelocytic leukemia]] | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2005-04-11: Initial approval for the treatment of [[Acute promyelocytic leukemia]]. | ||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Amnoid, Amnolake | ||
| − | + | [[Category:Drugs]] | |
| − | + | [[Category:Oral medications]] | |
| − | [[Category: | + | [[Category:Retinoids]] |
| − | |||
| − | |||
| − | |||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| + | |||
| + | [[Category:PMDA approved in 2005]] | ||
Latest revision as of 20:21, 27 June 2024
Mechanism of action
From the NCI Drug Dictionary: An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.
Diseases for which it is used
History of changes in PMDA indication
- 2005-04-11: Initial approval for the treatment of Acute promyelocytic leukemia.
Also known as
- Brand names: Amnoid, Amnolake